Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab with chemotherapy, with or without bevacizumab · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with persistent, recurrent or metastatic cervical cancer and PD-L1 combined positive score of at least 1 by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The regimen adds PD-1 inhibition to chemotherapy, with a bevacizumab option, in a defined cervical cancer population.
What research teams should watch
Capture PD-L1 CPS and the selected backbone and document when bevacizumab is included.
PRIMARY RECORDS